INVESTABOT
Equity Research
XNAS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Regeneron Pharmaceuticals (REGN) had 2 Form 144 pre-sale notices filed on 2026-08-10. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At le…
Regeneron Pharmaceuticals (REGN) had 1 Form 144 pre-sale notice filed on 2026-07-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At lea…
TL;DR: Regeneron posted Q1 2026 revenue of $3.6 billion, up 19% from $3.03 billion a year ago, driven by explosive growth across its drug portfolio.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/10/2026 | Zoghbi Huda Y | — | OPTION_EXERCISE | -800 | — | — |
| 8/10/2026 | Zoghbi Huda Y | — | SELL | -800 | $800 | $640,000 |
| 8/10/2026 | Zoghbi Huda Y | — | OPTION_EXERCISE | 800 | $377 | $301,352 |
| 8/10/2026 | Guarini Kathryn | — | OPTION_EXERCISE | -400 | — | — |
| 8/10/2026 | Guarini Kathryn | — | SELL | -400 | $800 | $320,000 |
| 8/10/2026 | Guarini Kathryn | — | OPTION_EXERCISE | 400 | $719 | $287,748 |
| 7/2/2026 | RYAN ARTHUR F | — | SELL | -200 | $650 | $130,030 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -1 | $712 | $712 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -2 | $711 | $1,422 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -6 | $709 | $4,257 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -4 | $707 | $2,830 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -7 | $707 | $4,947 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -14 | $706 | $9,878 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -24 | $703 | $16,883 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -15 | $702 | $10,537 |
| 5/1/2026 | RYAN ARTHUR F | — | SELL | -5 | $702 | $3,509 |
| 4/1/2026 | RYAN ARTHUR F | — | SELL | -1 | $771 | $771 |
| 4/1/2026 | RYAN ARTHUR F | — | SELL | -3 | $773 | $2,318 |
| 4/1/2026 | RYAN ARTHUR F | — | SELL | -8 | $774 | $6,189 |
| 4/1/2026 | RYAN ARTHUR F | — | SELL | -14 | $776 | $10,858 |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 8,446,366 | $8,877,384,199 | — | 8/13/2024 |
| Vanguard Group | 9,075,153 | $7,004,838,346 | — | 1/29/2026 |
| BlackRock | 8,947,735 | $6,913,378,662 | 2.4% | 5/13/2026 |
| BlackRock | 8,741,270 | $6,747,123,706 | — | 2/12/2026 |
| BlackRock | 9,113,506 | $5,682,635,642 | 1.9% | 8/7/2026 |
| State Street | 4,664,478 | $3,603,962,282 | 0.1% | 5/15/2026 |
| State Street | 4,660,808 | $3,597,537,871 | — | 2/13/2026 |
| JP Morgan Chase | 4,336,806 | $3,249,526,404 | 8.4% | 5/13/2026 |
| JP Morgan Chase | 4,002,160 | $3,089,148,831 | — | 2/11/2026 |
| State Street | 4,834,688 | $3,014,621,356 | 3.6% | 8/7/2026 |
| JP Morgan Chase | 3,774,199 | $2,384,577,378 | -13.0% | 8/12/2026 |
| Fidelity (FMR) | 2,319,566 | $1,790,403,167 | — | 2/17/2026 |
| Fidelity (FMR) | 1,518,192 | $1,173,016,067 | -34.5% | 5/15/2026 |
| Goldman Sachs | 1,504,658 | $1,162,559,093 | 13.3% | 5/15/2026 |
| Morgan Stanley | 1,389,323 | $1,072,379,189 | — | 5/27/2026 |
| Goldman Sachs | 1,327,627 | $1,024,755,473 | — | 3/25/2026 |
| Morgan Stanley | 1,319,329 | $1,019,369,158 | -5.0% | 5/15/2026 |
| AQR Capital | 1,231,008 | $946,005,238 | 23.6% | 5/15/2026 |
| Morgan Stanley | 1,397,712 | $871,531,343 | 5.9% | 8/13/2026 |
| Goldman Sachs | 1,334,291 | $831,983,461 | -11.3% | 8/14/2026 |